ID

15502

Descrizione

Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00151086

collegamento

https://clinicaltrials.gov/show/NCT00151086

Keywords

  1. 01/06/16 01/06/16 -
Caricato su

1 giugno 2016

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0

Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Prostate Cancer NCT00151086

Eligibility Prostate Cancer NCT00151086

Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI-1
C1512693
patients must have a histologic diagnosis of adenocarcinoma of the prostate. (no evidence of brain metastasis or untreated spinal cord compression.)
Descrizione

adenocarcinoma of the prostate

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0600139
patients on total androgen suppression therapy must undergo nonsteroidal antiandrogen withdrawal and demonstrate at rising psa (prostate specific antigen) 4 weeks after withdrawal for flutamide and 6 weeks after withdrawal for bicalutamide or nilutamide.
Descrizione

androgen suppression therapy

Tipo di dati

boolean

patients must have measurable soft tissue disease or evaluable (abnormal bone scan and/or elevated psa). if psa is the only evidence of progressive disease it must be greater than or equal to 4ng/ml.
Descrizione

measurable soft tissue disease

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0263978
UMLS CUI [1,2]
C1513041
adequate bone marrow, renal and liver function
Descrizione

bone marrow renal and liver function

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0005953
UMLS CUI [2]
C0232804
UMLS CUI [3]
C0232741
ecog (eastern cooperative oncology group) performance status of 0-2 (a measure of general well being on a scale of 0-5 where 0 represents asymptomatic and 5 represents death)
Descrizione

ecog

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1520224
must be at least 18 years of age
Descrizione

age

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001779
must have a life expectancy of greater than or equal to 12 weeks
Descrizione

life expectancy

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0023671
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI-1
C0680251
have previously received vinca alkaloid-based cytotoxic chemotherapy or radiation to greater than or equal to 50% of the total bone marrow.
Descrizione

vinca alkaloid-based cytotoxic chemotherapy

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0042672
UMLS CUI [1,2]
C0392920
UMLS CUI [2]
C1522449
evidence of brain metastasis
Descrizione

brain metastasis

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0220650
spinal cord compression
Descrizione

spinal cord compression

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0037926
prior malignancy except for in situ carcinoma, nonmelanoma skin cancer, or adequately treated malignancy that has been inactive for less than 3 years
Descrizione

prior malignancy

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0006826
patients with preexisting neuropathy of greater than or equal to grade 2
Descrizione

preexisting neuropathy

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0442874
active gastrointestinal disease, or a disorder that alters gastrointestinal motility or absorption
Descrizione

active gastrointestinal disease

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0017178

Similar models

Eligibility Prostate Cancer NCT00151086

Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
Inclusion Criteria
C1512693 (UMLS CUI-1)
adenocarcinoma of the prostate
Item
patients must have a histologic diagnosis of adenocarcinoma of the prostate. (no evidence of brain metastasis or untreated spinal cord compression.)
boolean
C0600139 (UMLS CUI [1])
androgen suppression therapy
Item
patients on total androgen suppression therapy must undergo nonsteroidal antiandrogen withdrawal and demonstrate at rising psa (prostate specific antigen) 4 weeks after withdrawal for flutamide and 6 weeks after withdrawal for bicalutamide or nilutamide.
boolean
measurable soft tissue disease
Item
patients must have measurable soft tissue disease or evaluable (abnormal bone scan and/or elevated psa). if psa is the only evidence of progressive disease it must be greater than or equal to 4ng/ml.
boolean
C0263978 (UMLS CUI [1,1])
C1513041 (UMLS CUI [1,2])
bone marrow renal and liver function
Item
adequate bone marrow, renal and liver function
boolean
C0005953 (UMLS CUI [1])
C0232804 (UMLS CUI [2])
C0232741 (UMLS CUI [3])
ecog
Item
ecog (eastern cooperative oncology group) performance status of 0-2 (a measure of general well being on a scale of 0-5 where 0 represents asymptomatic and 5 represents death)
boolean
C1520224 (UMLS CUI [1])
age
Item
must be at least 18 years of age
boolean
C0001779 (UMLS CUI [1])
life expectancy
Item
must have a life expectancy of greater than or equal to 12 weeks
boolean
C0023671 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI-1)
vinca alkaloid-based cytotoxic chemotherapy
Item
have previously received vinca alkaloid-based cytotoxic chemotherapy or radiation to greater than or equal to 50% of the total bone marrow.
boolean
C0042672 (UMLS CUI [1,1])
C0392920 (UMLS CUI [1,2])
C1522449 (UMLS CUI [2])
brain metastasis
Item
evidence of brain metastasis
boolean
C0220650 (UMLS CUI [1])
spinal cord compression
Item
spinal cord compression
boolean
C0037926 (UMLS CUI [1])
prior malignancy
Item
prior malignancy except for in situ carcinoma, nonmelanoma skin cancer, or adequately treated malignancy that has been inactive for less than 3 years
boolean
C0006826 (UMLS CUI [1])
preexisting neuropathy
Item
patients with preexisting neuropathy of greater than or equal to grade 2
boolean
C0442874 (UMLS CUI [1])
active gastrointestinal disease
Item
active gastrointestinal disease, or a disorder that alters gastrointestinal motility or absorption
boolean
C0017178 (UMLS CUI [1])

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial